NCT07204964 - A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above | Biotech Hunter

Enrollment

960

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

September 18, 2026

Study Completion Date

September 18, 2026

Conditions

Influenza, Human

Interventions

BIOLOGICAL

Flu mRNA (Formulation B1)

One dose of Flu mRNA (Formulation B1) received intramuscularly.

BIOLOGICAL

Flu mRNA (Formulation B3)

One dose of Flu mRNA (Formulation B3) received intramuscularly.

BIOLOGICAL

Flu mRNA(Formulation A)

One dose of Flu mRNA (Formulation A) received intramuscularly.

COMBINATION_PRODUCT

Comparator 1

One dose of Comparator 1 received intramuscularly.

COMBINATION_PRODUCT

Comparator 2

One dose of Comparator 2 received intramuscularly.

COMBINATION_PRODUCT

Comparator 3

One dose of Comparator 3 received intramuscularly.